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Abstract
Background: The aim of this study was to evaluate the survival benefit of radical surgery with additional extensive
upper abdominal procedures (EUAS) for the treatment of stage IIIC and IV ovarian cancer with bulky upper
abdominal disease (UAD).
Methods: An observational study was conducted between 2009 and 2012 involving two different surgical teams.
Team A was composed of the “believers” in EUAS and Team B the “non-believers” in EUAS. Patients were divided
into a radical surgery group (EUAS group) or a standard surgery group (non-EUAS group) according to whether or
not they had received EUAS. All patients underwent primary cytoreductive surgery with the goal of optimal
debulking (≤1 cm); this was reviewed in the pelvis, middle abdomen, and upper abdomen. The baseline for the
two groups was optimal cytoreduction in both the pelvis and middle abdomen. Progression-free survival (PFS) was
evaluated.
Results: Radical surgery was performed in 70.7 % (82/116) and 12.7 % (30/237) of the patients by Teams A and B,
respectively. The study groups had similar clinicopathologic characteristics. The median PFS and OS were significantly
improved in the radical surgery group, compared with standard surgery groups (PFS: 19.5 vs. 13.3 months, HR: 0.61;
95 % CI: 0.46–0.80, P < 0.001; OS: not reached vs. 39.3 months, HR: 0.47; 95 % CI: 0.30–0.72, P < 0.001). Positive predictors
of complete cytoreduction were treatment with neoadjuvant chemotherapy, improved American Society of
Anesthesiologists performance status, and the absence of bowel mesenteric carcinomatosis.
Conclusions: Radical surgery lengthens the PFS and overall survival times of ovarian cancer patients with bulky UAD.
However, a well-designed randomized trial is needed to confirm the present results.
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Background
Epithelial ovarian cancer (EOC) is the most lethal of all
gynecological cancers [1]. The goal of primary cytore-
duction for advanced EOC is advocated to be no visible
residual disease,which has been confirmed in several
studies, but only less than 30 % of women with bulky
upper abdominal disease (UAD) can achieve complete
cytoreduction [2, 3]. Thus, it still remains controversial
as to whether or not patients with bulky UAD can bene-
fit from upper abdominal procedures (EUAS). It has
been suggested that upper abdominal procedures should
only be performed when complete or optimal cytoreduc-
tion is attainable [4–6].
In China, only a few surgeons are willing to undertake
EUAS because most lack the relevant surgical skills, or
there is tension between patients and physicians regard-
ing the invasiveness of the treatment. Consequently, to
date, there have been no Chinese studies in this area [7].
Most of the surgeons tend to accept neoadjuvant
chemotherapy followed by surgery as the standard ap-
proach, which is in line with the result of EORTC 55971
study reported in 2010 [8].
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Herein, we define radical surgery as the EUAS proce-
dures complementing an optimal cytoreduction within
the middle abdomen and the pelvis. These procedures
include diaphragmatic peritonectomy, hepatic resection,
splenectomy, distal pancreatectomy, cholecystectomy,
and the resection of tumor on the surface of upper ab-
dominal organs. Standard surgery is defined as the opti-
mal surgical outcome achieved in both the middle
abdomen and the pelvis (including small and/or large
bowel resections), and the subsequent attempt to resect
tumor nodes measuring ≥1 cm in the upper abdomen.
An exploratory study was conducted to compare the
survival after radical surgery with standard surgery in
patients with bulky stage IIIC and IV ovarian cancer.
Methods
Patients
A single institute observational study was conducted be-
tween 2009 and 2012. Patients who were diagnosed with
stage IIIC or IV epithelial ovarian cancer with bulky UAD
were identified and the data were collected retrospectively,
which was approved by Fudan University Shanghai Cancer
Center Institutional Review Board (SCCIRB-090371-2).
The residual disease was evaluated in the pelvis, middle
abdomen, and upper abdomen, respectively. In the stand-
ard surgery (non-EUAS surgery) group, patients with re-
sidual disease measuring ˃1 cm in the pelvis and middle
abdomen were excluded.
Medical records were abstracted for the following data:
age at primary cytoreduction; International Federation of
Gynecology and Obstetrics (FIGO) stage; histology;
tumor grade; Eastern Cooperative Oncology Group
(ECOG) performance status; American Society of Anes-
thesiologists (ASA) score; preoperative serum cancer
antigen (CA125); ascites and extent of disease (catego-
rized as solitary, localized, and carcinomatosis defined as
diffused involving of the peritoneal surfaces) at primary
surgery; cytoreductive procedures; residual disease after
primary cytoreduction; surgeons involved; type of front-
line chemotherapy; estimated blood loss; intraoperative
blood transfusion; operative time; intensive care unit
(ICU) stay; length of hospitalization; postoperative 30-
day morbidity and mortality; progression-free survival
(PFS), follow-up time; and survival time. The computed
tomography (CT) or magnetic resonance imaging (MRI)
scan was reviewed by the radiologist (CY) in all possible
patients to re-evaluate the upper abdominal disease.
Definitions
There were two different surgical teams: Team A was
the “believers” and “deeds over words” regarding EUAS
procedures, who attempted to resect any macroscopic
disease; Team B was “non-believers” in EUAS.
PFS was defined as the time from initial treatment to
the diagnosis of the first recurrence or last follow-up,
whichever came first. Overall survival (OS) was defined
as the time from initial treatment to death or last
follow-up. Recurrence was diagnosed by one or more of
the following: physical examination; elevated CA-125
levels as defined by the Gynecologic Oncology Inter-
group [9]; and radiological imaging.
The abdominal tumor site (pelvis, middle abdominal,
and upper abdominal disease) at primary cytoreduction
was defined as previously described [10]. Optimal cytore-
duction was defined as residual disease measuring ≤1 cm,
but the cut-off points of 0 cm and 0.5 cm were also used
to evaluate the impact on survival.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware package for Windows (version 16.0). The Chi-
square or Mann–Whitney U tests were used to identify
differences in the baseline level between the two groups.
Median survival was evaluated using the Kaplan–Meier
method and differences were determined using the log-
rank test. The Cox proportional hazards regression
model was used to identify prognostic factors. Logistic
regression analysis was conducted to detect the predic-
tors of complete cytoreduction. A P-value of <0.05 was
considered as being statistically significant.
Results
Baseline and patient characteristics
Three hundred and fifty-three patients were included in
this observational study. Of these patients, 112 received
radical surgery including EUAS procedures, and 241 re-
ceived standard surgery. In radical surgery group, Team
A did 82 cases (73.2 %) radical surgery; and Team B did
30 (26.8 %) radical surgery. Altogether Team A did sur-
gery in 116 patients, and Team B did surgery in 237
patients. Patient baseline characteristics as well as the
imaging findings regarding the disease within the upper
abdomen were similar between the two groups (Tables 1
and 2). In the radical surgery group, eight (7.1 %) pa-
tients were upstaged for pleural metastasis and 21
(18.8 %) were diagnosed with stage IV ovarian cancer in
the EUAS group as compared with 26 (10.8 %) patients
in the non-EUAS group. In the radical surgery group,
the optimal cytoreduction achieved in the pelvis and
middle abdomen was 98.2 % and 97.3 %, respectively; all
patients in the standard surgery group underwent opti-
mal cytoreduction. However, more patients in the radical
surgery group had microscopic residual disease, both in
the pelvis (82.1 % versus 53.5 %) and the middle abdo-
men (53.6 % versus 28.6 %) when compared with those
patients in the control group.
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Surgical outcomes
There were significant differences between radical sur-
gery involving EUAS and standard surgery in terms of
estimated blood loss, intraoperative blood transfusion,
operative time, ICU stay, and length of hospitalization
(Table 3). In the EUAS group, optimal cytoreduction
was performed in 107 patients (95.5 %), and in 76 pa-
tients (67.9 %) complete cytoreduction was achieved in
the upper abdomen. However, no patients achieved
complete cytoreduction in the control arm, and only
43.6 % received optimal surgery.
The extensive upper abdominal procedures performed
in the radical surgery group included diaphragm perito-
nectomy, full-thickness diaphragm resection, resection of
the lesser omentum, splenectomy, liver resection, distal






Median age (range) 56 years (35–82) 56 years (26–79) 1.000
FIGO stage 0.045
Stage IIIC 91(81.2 %) 215(89.2 %)




111 (99.1 %) 240 (99.6 %)
Fallopian tube
cancer
1 (0.9 %) 0 (0 %)
Primary peritoneal
cancer
0 (0 %) 1 (0.4 %)
Histology 0.084
Serous 100(89.3 %) 202(83.8 %)
Mucinous 0(0 %) 2(0.8 %)
Endometrioid 2(1.8 %) 2(0.8 %)
Clear cell 2(1.8 %) 5(2.1 %)
Others 8(7.2 %) 30(12.4 %)
Grade 0.787
Grade1 0(0 %) 2(0.8 %)
Grade 2 9(8.0 %) 16(6.6 %)
Grade 3 102(91.1 %) 218(90.5 %)




0 57(50.9 %) 95(39.4 %)
1 49(43.8 %) 126(52.3 %)
2 6(5.4 %) 20(8.3 %)
ASA status 0.358
1 59(52.7 %) 107(44.4 %)
2 51(45.5 %) 127(52.7 %)













Yes 20 (17.9 %) 35 (14.5 %)











Yes 78 (69.6 %) 160 (66.4 %)
No 34 (30.4 %) 81 (33.6 %)




0 cm 92(82.1 %) 129(53.5 %)
0.1–0.5 cm 15(13.4 %) 71(29.5 %)
0.5–1 cm 3(2.7 %) 41(17.0 %)
>1 cm 2(1.8 %) 0(0 %)
Residual disease in middle abdomen <0.001
0 cm 60(53.6 %) 69(28.6 %)
0.1–0.5 cm 40(35.7 %) 93(38.6 %)
0.5–1 cm 9(8.0 %) 79(32.8 %)
>1 cm 3(2.7 %) 0(0 %)
Total 112 241
Abbreviations: FIGO International Federation of Gynecology and Obstetrics,
ECOG Eastern Cooperative Oncology Group, ASA American Society of
Anesthesiologists, NA not available
*Tested by Chi-square or Mann–Whitney U. b Thoracic exploration was
performed in 13 patients and 8 patients were upstaged for pleural metastasis
Table 2 Preoperative imaging for the evaluation of upper
abdominal disease





Right diaphragm 29 (76.3 %) 49 (68.1 %) 0.364
Left diaphragm 6 (15.8 %) 19 (26.4 %) 0.207
The surface of liver 9 (23.7 %) 12 (16.7 %) 0.373
The surface of spleen 0 (0 %) 3 (4.2 %) 0.202
Portahepatis 7 (18.4 %) 6 (8.3 %) 0.119
Perisplenicregion 9 (23.7 %) 17 (23.6 %) 0.993
Spleen parenchyma 4 (10.5 %) 2 (2.8 %) 0.099
Lesser omentum 10 (26.3 %) 10 (13.9 %) 0.108
Diaphragmatic lymph
node
24 (64.9 %) 35 (48.6 %) 0.107
Total 38 72
*Tested by Chi-square
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pancreatectomy, cholecystectomy, thoracic exploration,
and resection of tumor on the surface of the liver, stom-
ach, spleen, the gallbladder fossa and the renal capsule
(Table 4). In the standard surgery group, only a few proce-
dures involving upper abdominal surgery were conducted
(Table 5). Radical surgery was performed in 73.2 % (82/
112) and 12.4 % (30/241) of the patients by Teams A and
B, respectively. When the data were divided into two pe-
riods from June 2009 to June 2011 and from July 2011 to
December 2012, the level of performance of EUAS was
Table 3 Surgical outcomes between radical surgery with
extensive upper abdominal procedures and standard surgery
Variable Radical surgery
group (n = 112)
Standard surgery





0 cm 46 (41.1 %) 0 (0 %)
0.1–0.5 cm 46 (41.1 %) 27 (11.2 %)
0.5–1 cm 15 (13.4 %) 78 (32.4 %)




0 cm 76(67.9 %) 0(0 %)
0.1–0.5 cm 24(21.4 %) 30(12.4 %)
0.5–1 cm 10(8.9 %) 75(31.1 %)









Median volume 800 ml 400 ml
(range) (0–3200) (0–2400)
Operative time <0.001
Median 171 min 124 min
(range) (75–360) (51–318)
ICU stay 0.018
Yes 28 (25.0 %) 35 (14.5 %)




Mean 19.96 days 10.39 days
(range) (4–190)b (4–42)
*Tested by Chi-square or Mann–Whitney U.b33 patients (29.5 %) in radical
surgery group participated in a phase II clinical trial on intraperitoneal
chemotherapy and were assigned to receive IP chemotherapy for 4 cycles
weekly post operative in hospital, whereas only 7 patients (1.7 %) in standard
surgery group
participated in this trial and received IP chemotherapy. One patient stayed in
hospital for 190 days because she received all the cycles of IP and IV chemotherapy
in hospital
Table 4 The procedures of extensive upper abdominal surgery
in radical surgery group (n = 112)
Procedure No. of patients Percent
Left side diaphragm peritonectomy 1 0.9 %
Right side diaphragm peritonectomy 79 70.5 %
Both sides diaphragm peritonectomy 20 17.9 %
Full-thickness diaphragm resection 7 6.3 %
Thoracic exploration 13 11.6 %
Resection of lesser omentum 35 31.3 %
Splenectomy 17 15.2 %
Liver resection 8 7.1 %
Distal pancreatectomy 2 1.8 %
Cholecystectomy 1 0.9 %
Resection of the tumor on the surface of
liver
27 24.1 %
Resection of the tumor on the surface of
stomach
8 7.1 %
Resection of the tumor on the surface of
spleen
5 4.5 %
Resection of the tumor in the gallbladder
fossa
5 4.5 %
Resection of the renal capsule 1 0.9 %
Table 5 The procedures of upper abdominal surgery in
standard surgery group (n = 241)
Procedure No. of patients Percent
Diaphragm stripping 4 1.7 %
Diaphragm peritonectomy 0 0 %
Full-thickness diaphragm resection 0 0 %
Thoracic exploration 0 0 %
Resection of lesser omentum 6 2.5 %
Splenectomy 8 3.3 %
Liver resection 0 0 %
Distal pancreatectomy 1a 0 %
Cholecystectomy 0 0 %
Resection of the tumor on the surface of
liver
3 1.2 %
Resection of the tumor on the surface of
stomach
2 0.8 %
Resection of the tumor on the surface of
spleen
1 0.4 %
Resection of the tumor in the gallbladder
fossa
0 0 %
Resection of the renal capsule 0 0 %
aDistal pancreatectomy was mentioned in this patient’s surgical records,
however pathology report showed there was no pancreatic tissue in the
pathological sections
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elevated in the case of both teams (Table 6). The positive
predictors of complete cytoreduction were as follows:
undergoing neoadjuvant chemotherapy; better ASA
performance status; and the absence of bowel mesen-
teric carcinomatosis (P = 0.006, P = 0.014 and P = 0.026,
respectively; Table 7).
In the standard surgery group, one patient died at
30 days after surgery because of a bowel obstruction, ab-
dominal hemorrhage, and disease progression. However,
there was no surgery-related death in the radical surgery
group. The rate of Memorial Sloan-Kettering Cancer
Centre (MSKCC) Grade III/IV complications in the two
groups were 8.0 % (9/112) and 2.9 % (7/241), respect-
ively. Thoracentesisor chest tube placement was more
Table 6 Patients’ distributions of extensive upper abdominal
surgery by surgeons
Years of the data
Groups 2009.6–2011.6 2011.7–2012.12
Team A Team B Team A Team B
Radical surgery
group (n = 112)
29 (65.9 %) 9 (8.8 %) 53 (73.6 %) 21 (15.6 %)
Standard surgery
group (n = 241)
15 (34.1 %) 93 (91.2 %) 19 (26.4 %) 114 (84.4 %)
Total 44 102 72 135
Team A described as the “believers” and “deed over words” in EUAS (extensive
upper abdominal surgery) procedures, trying to resect any macroscopic
disease, and did 82 cases (73.2 %) radical surgery; Team B not believing EUAS,
and only did 30 (26.8 %) radical surgery
Table 7 Variables affecting primary surgical outcomes (R0, R0.5)
in patients with bulky stage IIIc and IV ovarian cancera,b





−1.004 0.367 0.006 0.366 0.178 0.752
ASA score 0.772 0.314 0.014 2.165 1.170 4.006
Bowel mesenteric
carcinomatosisc




−0.907 0.301 0.003 0.404 0.224 0.729
ECOG performance 0.639 0.190 0.001 1.895 1.307 2.747
B beta coefficient, SE standard error, RR relative risk, 95 % CI 95 % confidence
interval, R0 complete cytoreduction, R0.5 cut-off point of residual disease in
overall all was 0.5 cm, ASA American Society of Anesthesiologists, ECOG
Eastern Cooperative Oncology Group
aLogistic regression analysis
b Variable “surgical team” was the most significant determinant of surgical
outcomes, but it was not included into this model
c It is a variable found in surgery, but interestingly, it is a predictor of
complete cytoreduction not the predictor of small residual disease of 0.5 cm,
so it was included in the Logistic regression model






Thoracentesis/chest tube placement 9(8.0 %) 4(1.7 %)
Pulmonaryembolism 1(0.9 %) 1(0.4 %)
Deep venous thrombosis 1(0.9 %) 0
Cerebral infarction 0 1(0.4 %)
Bowel obstruction 2(1.8 %) 8(3.3 %)
Wound infection 2(1.8 %) 2(0.8 %)
Abdominalinfections 1(0.9 %) 13(5.4 %)
Pneumonia 1(0.9 %) 1(0.4 %)
Urinary tract infection 0 1(0.4 %)
Gastroenteritis 1(0.9 %) 0
Heart failure/arrhythmia 1(0.9 %) 0
Relaparotomy for hemorrhage 1(0.9 %) 1 (0.4 %)
Blood transfusion for hemorrhage 0 2(0.8 %)
Median PRBC 0 8u/4ua
Intestinal fistula 0 1(0.4 %)
MSKCC Grade III/IVb 9 (8.0 %) 7 (2.9 %)
Mortality (MSKCC Grade V) 0 1(0.4 %)
EUAS: extensive upper abdominal surgery. PRBC: Packed Red Blood Cell
aTwo patients required blood transfusion for hemorrhage, with one received
8u PRBC and the other one received 4u PRBC. bMemorial Sloan-Kettering Cancer
Center (MSKCC) surgical secondary events gradingsystem, see reference





Thoracentesis/chest tube placement 6(5.2 %) 7(3.0 %)
Pulmonaryembolism 1(0.9 %) 1(0.4 %)
Deep venous thrombosis 0 1(0.4 %)
Cerebral infarction 1(0.9 %) 0
Bowel obstruction 0(0.9 %) 10(4.2 %)
Wound infection 1(0.9 %) 3(1.3 %)
Abdominal infections 4(3.4 %) 10(4.2 %)
Pneumonia 0 2(0.8 %)
Urinary tract infection 0 1(0.4 %)
Gastroenteritis 1(0.9 %) 0
Heart failure/arrhythmia 1(0.9 %) 0
Relaparotomy for hemorrhage 0(0.0 %) 2 (0.8 %)
Blood transfusion for hemorrhage 0 2(0.8 %)
Intestinal fistula 0 1(0.4 %)
MSKCC Grade III/IV 7 (6.0 %) 9 (3.8 %)
Mortality (MSKCC Grade V) 0 1(0.4 %)
Team A did 82 cases (73.2 %) radical surgery; and Team B only did 30 (26.8 %)
radical surgery
There were 2 cases of relaparotomy for hemorrhage, 2 blood transfusion for
hemorrhage, 1 intestinal fistula and 1 death in Team B, with no case in Team
A. Since there were more radical surgery in Team A, 6 cases (5.2 %) had chest
tube placement in Team A, compared with 7 (3.0 %) in Team B
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common in the radical surgery group (8.0 % versus
1.7 %; Table 8). There was no significant difference in
morbidity and mortality between Teams A and B
(Table 9).
Survival predictors
The median follow-up time was 25.3 (range, 16–65)
months. The median PFS was 19.5 months and 13.3 months
in the radical surgery and standard surgery groups, respect-
ively (P < 0.001; hazard ratio (HR), 0.61; 95 % confidence
interval (CI), 0.46–0.80; Fig. 1a), with an estimated 5-
year PFS of 15 % and 10 %, respectively. The median
survival time was 39.3 months in the standard surgery
group; however, in the radical surgery group the me-
dian survival time was not reached (P < 0.001; HR,
0.47; 95 % CI, 0.30–0.72) (Fig. 1b). Residual disease in
the upper abdomen (HR, 1.29; 95 % CI, 1.16–1.44;
P = 0.002) and FIGO stage (HR, 1.62; 95 % CI, 1.16–
2.27; P = 0.001) were found to be the predictors of PFS
using Cox regression analysis (Table 10).
Patients with residual disease in the upper abdomen
measuring <0.5 cm had a median PFS of 22.1 months,
as compared with 12.9 months in patients with residual
disease measuring >0.5 cm (P < 0.001; HR, 0.51; 95 %
CI, 0.39–0.66; Fig. 2a). Moreover, the median PFS could
reach 23.3 months in patients with microscopic disease
in the upper abdomen (Figs. 2b and 3).
Discussion
The role of radical surgery with an additional upper
abdominal cytoreduction
It is well established that EUAS could increase the pro-
portion of patients achieving optimal cytoreduction as
well as complete cytoreduction [4, 5, 11–13]. However,
it is still unclear as to which patients would benefit from
EUAS. Rodriguez and colleagues reviewed 2655 patients
enrolled in the Gynecologic Oncology Group 182 trial
from 2001 to 2004 who had achieved optimal cytoreduc-
tion (<1 cm) [4]. A total of 482 (18.1 %) patients re-
ceived upper abdominal procedures. These authors
reported that both the PFS (18.2 versus 14.8 months;
P < 0.01) and OS (49.8 versus 43.7 months; P = 0.01)
were higher in patients who did not require an upper
abdominal procedure relative to patients who required
upper abdominal procedures; they suggested that requir-
ing upper abdominal surgery was an indicator of more
extensive disease, which would have a negative impact
on survival. When subgroup analysis was performed in
patients with a high disease burden in the upper ab-
domen (n = 1636), it did not reveal an improved PFS
(P = 0.43) in the 482 (29 %) patients who had undergone
upper abdominal surgery relative to patients who had
not, while the OS exhibited a modest improvement of
3.8 months. However, in the subset of patients who had
received upper abdominal surgery, when considering
postoperative residual disease, both the PFS (20.2 versus
13.7 months; P < 0.01) and the OS (54.6 versus 40.4 months;
P < 0.01) were significantly prolonged in patients with
complete cytoreduction (n = 141) relative to patients with
minimal residual disease measuring <1 cm (n = 341). The
authors concluded that in patients who required upper ab-
dominal surgery, only the increased rate of complete cytor-
eduction could translate into prolonged OS [4]. However,
regarding the MSKCC studies, their data demonstrated that
EUAS significantly improved PFS and OS [13, 14]. In
addition, the most recent study from this center has shown
that patients with macroscopic residual disease ≤1 cm
who required EUAS did not have a worse OS than those
who did not require EUAS (45 months versus 52 months;
P = 0.56) [5].
Unlike previous studies [4–6, 11–14], the current
study was unique with respect to patient enrollment.
First, it was an observational study and we only in-
cluded patients from a single institution with bulky
A B
Fig. 1 Survival analysis of EUAS group vs. non-EUAS group in bulky stage IIIC and IV EOC. a: Progression-free survival curve; b: Overall survival
curve (Analysis as of May 6, 2014)
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upper abdominal disease, who had achieved optimal
primary resection in both the pelvis and middle abdo-
men in a recent period. Second, although patient se-
lection bias still existed in the present study, the
difference in the inherent tumor biology between the
radical surgery group and the standard surgery group
was balanced to a certain degree. Consequently, we
could specifically analyze the role of EUAS and obtain
results as to whether or not patients could obtain a sur-
vival benefit from EUAS.
In the present study, a 6.2-month prolongation in the
median PFS was observed in patients who had under-
gone additional EUAS. Although the data were imma-
ture, a significant difference in OS was also observed.
Because of the EUAS procedures, eight patients were
upstaged for pleural metastasis. Therefore, thoracic ex-
ploration in EUAS could obtain an exact FIGO staging
in patients with a heavy diaphragm tumor burden, espe-
cially those with an untapped pleural effusion.
As diaphragmatic peritonectomy was performed most
frequently regarding EUAS, pleural effusion was the
most common morbidity [15]. However, symptomatic
pleural effusion can be well managed through thoracent-
esis or chest tube placement. The other morbidities such
as pulmonary embolism, deep venous thrombosis, bowel
obstruction, abdominal infections, and wound infection
were not significantly increased in the radical surgery
group. In addition, there was no surgery-related death in
the radical surgery group. Although EUAS procedures
were complicated, radical surgery did not increase the
morbidity and mortality when compared with standard
surgery.
“Maximal” cytoreduction and residual disease in bulky
ovarian cancer
Upper abdominal surgical procedures have proved to be
more practical than most surgeons had anticipated. In
our cohort, 89.3 % of the patients in the radical surgery
Fig. 2 PFS by residual disease in the upper abdomen after primary cytoreductive surgery. a: comparison of residual disease between <0.5 cm
vs. >0.5 cm; b: comparison of residual disease between 0 cm vs. >0 cm
Table 10 Univariate and multivariate analysis of progression-free survival
Characteristic N Median PFS Univariate Multivariate
(months) P value HR (95 %CI) P value
FIGO stage 0.004 1.62 (1.16–2.27) 0.001
IIIC 305 15.3
IV 46 11.4
Residual disease in upper
abdomen
<0.001 1.29 (1.16–1.44) 0.002
0 cm 75 23.3
0–0.5 cm 54 17.8
0.5–1 cm 85 13.5
>1 cm 137 12.6
Total 351 14.7
Abbreviations: N number of patients, FIGO International Federation of Gynecology and Obstetrics, PFS progression-free survival, HR hazard ratio, 95 % CI 95 %
confidence interval
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group achieved residual disease measuring <0.5 cm and
showed a survival advantage (Table 3). Additionally, the
surgical outcome was accurately predicted by logistic re-
gression analysis of CT/MRI scan data regarding the
upper abdomen (Table 11). Moreover, residual disease in
the upper abdomen was found to be one of the predic-
tors of PFS (Table 10).
Although surgeons have made more efforts regarding
how to best describe optimal cytoreduction in ovarian
cancer, we believe that it is still not clear as to what consti-
tutes “maximal” cytoreduction, or how to improve the sur-
gical approach among the different teams, institutions,
and countries. Complete cytoreduction is not equally ap-
plicable between neoadjuvant chemotherapy followed by
interval cytoreductive surgery and primary cytoreductive
surgery. Neoadjuvant chemotherapy can eliminate carcin-
omatosis in the peritoneum if it is chemosensitive, but its
effects differ in patients undergoing “maximal” cytoreduc-
tion and peritonectomy. In the present study, Team B
resected patients with tumor masses measuring >1 cm but
left the peritoneal carcinomatosis in the upper abdomen;
this was considered suboptimal by Team A. Thus, differ-
ent interpretations of the term “maximal” can result in dif-
ferent surgical outcomes.
In the radical surgery group, we considered the residual
disease as ≤0.5 cm when peritoneal carcinomatosis was
cytoreduced to microscopic residual by electronic knife,
while not by en-block peritonectomy. We did not find a
survival difference between lesions measuring 0.1–0.5 cm
and 0 cm when residual disease was evaluated in either
the upper abdomen alone or the whole abdomen (Figs. 3
and 4a). The common pattern of tumor involvement in
the diaphragmatic and other upper regions of the abdom-
inal peritoneum was carcinomatosis (339/353; 96 %); con-
sequently, resection of all tumor nodes to a microscopic
residual size in these patients was usually impossible. In
our series, the cut-off point of 0.5 cm for residual disease
Table 11 Prediction of complete cytoreduction by
diaphagmatic imaging findings*
Tumor site N B SE P value* RR 95 % CI
Residual disease,
in overall









aLogistic regression analysis. N number of cases, B beta coefficient, SE standard
error, RR relative risk; 95 % CI 95 % confidence interval
Fig. 3 PFS by residual disease in upper abdomen after primary cytoreductive surgery. A comparison of residual disease among 0 cm, 0–0.5 cm,
0.5–1 cm, >1 cm
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is recommended for patients with bulky upper abdominal
disease. This is because a biological complete cytoreduc-
tion is always rare when tumor cells have spread to the
whole coelom (Figs. 4a, b; 5 and 6). However, a 41.1 %
complete cytoreduction was achieved in the radical sur-
gery group, so we should always keep in mind that
complete gross cytoreductions are generally accepted, par-
ticularly in patients with less bulky UAD or less aggressive
bowel carcinomatosis [3].
A longer operation time (≥4 h) did not improve the PFS,
but shortened the OS, although not significantly (data not
shown). Team A did 82 cases (73.2 %) radical surgery; and
Team B only did 30 (26.8 %) radical surgery. There
were 2 cases of relaparotomy for hemorrhage, 2 blood
transfusion for hemorrhage, 1 intestinal fistula and 1
death in Team B, with no case in Team A. Therefore,
EUAS performed by under-trained gynecologic surgeons
is not recommended because it can result in more mor-
bidity and mortality (Table 9).
Because of non-randomization, the weakness of our
study was potential selection bias. To minimize the bias




N Events PFS 
(months)
<0.5 cm 118 70 22.8
>0.5 cm 233 200 13.0
P<0.001, HR=0.51 (95% CI 0.39-0.67)
No. at risk
<0.5cm 118 86 36 11 4








0cm 45 26 23.1 0.48
0-0.5cm 73 44 22.1 0.50
0.5-1cm 93 81 14.0 0.92
>1cm 140 119 12.6 Reference
P<0.001, HR=0.76 (95% CI 0.67-0.85)
No. at risk
0cm 45 33 13 3 1
0-0.5cm 73 53 23 8 3
0.5-1cm 93 54 20 9 3




N Events PFS 
(months)
<0.5 cm 100 57 23.6
>0.5 cm 205 172 13.5
P<0.001, HR=0.50 (95% CI 0.37-0.67)
No. at risk
<0.5cm 100 75 33 10 4




N Events PFS 
(months)
<0.5 cm 18 13 12.9
>0.5 cm 28 28 10.5
P=0.055, HR=0.52 (95% CI 0.26-1.02)
No. at risk
<0.5cm 18 11 3 1
>0.5cm 28 11 3
Fig. 4 Survival analysis by residual disease in overall after primary cytoreductive surgery. a: PFS comparison of residual disease in overall among 0 cm,
0–0.5 cm, 0.5–1 cm, >1 cm; b: PFS comparison of residual disease in overall between <0.5 cm vs. >0.5 cm; c: PFS by residual disease in overall after primary
cytoreductive surgery in patients with FIGO stage IIIC. d Progression-free survival by residual disease in overall after primary cytoreductive surgery in
patients with FIGO stage IV







0 cm 76 17 Not reached 0.46
0-0.5cm 54 14 Not reached 0.53
0.5-1cm 85 49 35.3 1.16
>1cm 138 58 39.3 Reference
P=0.001, HR=0.77 (95% CI 0.65-0.89)
No. at risk
0cm 76 73 45 20 11
0-0.5cm 54 50 31 17 6
0.5-1cm 85 77 46 28 14
>1cm 138 125 73 28 9
B
Residual disease in 
upper abdomen
N Events OS 
(months)
<0.5 cm 130 31 Not reached
>0.5 cm 223 107 38.3
P<0.001, HR=0.45 (95% CI 0.30-0.68)
No. at risk
<0.5 cm 130 123 76 37 17
>0.5 cm 223 202 119 56 23
C
Residual disease in 
upper abdomen
N Events OS 
(months)
0 cm 76 17 Not reached
>0 cm 277 121 41.3
P=0.003, HR=0.47 (95% CI 0.29-0.79)
No. at risk
0 cm 76 73 45 20 11
>0 cm 277 252 150 73 29
Fig. 5 Overall survival by residual disease in upper abdomen after primary cytoreductive surgery. a: OS by residual disease in upper abdomen
after primary cytoreductive surgery; b: OS by residual disease in upper abdomen with a comparison of cut-off point R0.5 cm; c: OS by residual
disease in upper abdomen with a comparison of cut-off point R0 cm







0cm 46 9 Not reached 0.42
0-0.5cm 73 17 Not reached 0.48
0.5-1cm 93 52 37.9 1.11
>1cm 141 60 39.3 Reference
P=0.001, HR=0.75 (95% CI 0.63-0.89)
No. at risk
0cm 46 45 26 10 4
0-0.5cm 73 68 43 21 10
0.5-1cm 93 84 51 33 16




N Events OS 
(months)
<0.5 cm 119 26 Not reached
>0.5 cm 234 112 38.3
P<0.001, HR=0.44 (95% CI 0.29-0.67)
No. at risk
<0.5 cm 119 113 69 31 14




N Events OS 
(months)
0 cm 46 9 Not reached
>0 cm 307 129 43.0
P=0.022, HR=0.46 (95% CI 0.24-0.91)
No. at risk
0 cm 46 45 26 10 4
>0cm 307 280 169 83 36
Fig. 6 Overall survival by residual disease in overall after primary cytoreductive surgery. a: OS by residual disease in overall after primary
cytoreductive surgery; b: OS by residual disease in overall with a comparison of cut-off point R0.5 cm; c: OS by residual disease in overall with a
comparison of cut-off point R0 cm
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were analyzed in Table 1, and no significant difference
was found between two groups in the median age, pri-
mary tumor, histology, tumor grade, ECOG perform-
ance status, ASA status, CA125 level, Neoadjuvant
chemotherapy (NAC), ascites, and bowel mesenteric
carcinomatosis (p > 0.05). More patients with stage IV
disease were in radical surgery group, as stage IV dis-
ease required more radical surgery during the operation
(18.8 % vs. 10.8 %, p = 0.045). It is still not clear
whether or not patients with stage IV disease benefit
from radical surgery (Fig. 4d). However, the results of
the current study provide evidence for designing a ran-
domized clinical trial.
Conclusions
Extensive upper abdominal surgery lengthens the PFS and
OS of ovarian cancer patients with bulky upper abdominal
disease. Although these findings are based on short-term
follow-up data, long-term follow-up is in progress. A well-
designed randomized trial is needed to confirm the present
results.
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